search

Dan Roden, MD, CM

by Tiffany Jones

October 24, 2018

Dan Roden received his medical degree and trained in Internal Medicine at McGill University in Montreal.  He then went to Vanderbilt where, after fellowships in Clinical Pharmacology and Cardiology, he joined the faculty, and has remained there since.  His research program studies the phenotypic consequences of genomic variation focusing on pharmacogenetics and on arrhythmia susceptibility.  After serving as chief of the division of Clinical Pharmacology for 12 years, he was tasked in 2006 with leading Vanderbilt’s efforts in Personalized Medicine.  Under his leadership, Vanderbilt has become nationally- and internationally-recognized for cutting edge programs in this area: these include BioVU, the largest single-site collection (now >250,000) of DNA samples coupled to electronic health records in the world, and PREDICT, a program that puts genetic information on variable drug responses in patients’ electronic health records, and uses that information when target drugs are prescribed. He has been principal investigator for the Vanderbilt sites of the Pharmacogenomics Research Network since 2001 and of the Electronic Medical Records and Genomics (eMERGE) Network since 2007.

Dr. Roden has received the Leon Goldberg Young Investigator Award and the Rawls Palmer Progress in Science Award from the American Society for Clinical Pharmacology and Therapeutics; the Distinguished Scientist Award and the Douglas Zipes lectureship from the Heart Rhythm Society; the Distinguished Scientist Award and the inaugural Functional Genomics and Translational Biology Medal of Honor from the American Heart Association; and the Alumnus Lifetime Achievement Award and the Louis and Artur Lucian Award from McGill University.  He has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians, and fellowship in the American Association for the Advancement of Science.